<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04784910</url>
  </required_header>
  <id_info>
    <org_study_id>DW_DWP14012304</org_study_id>
    <nct_id>NCT04784910</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Efficacy and Safety of DWP14012 in Prevention of NSAIDs Induced Peptic Ulcer</brief_title>
  <official_title>A Multi-center, Randomized, Double-blind, Parallel-group, Active-controlled, Phase III Clinical Trial to Evaluate the Efficacy and Safety of DWP14012 in Prevention of NSAIDs Induced Peptic Ulcer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daewoong Pharmaceutical Co. LTD.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daewoong Pharmaceutical Co. LTD.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims to demonstrate the preventive effect of DWP14012 20 mg for peptic ulcer is&#xD;
      non-inferior to that of Lansoprazole 15 mg in terms of prevention of peptic ulcer and confirm&#xD;
      the safety of DWP14012 20 mg.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2021</start_date>
  <completion_date type="Anticipated">February 28, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects who develop peptic ulcer by Week 24 as assessed by investigator</measure>
    <time_frame>at 24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects who develop peptic ulcer by Week 12 as assessed by investigator</measure>
    <time_frame>at 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with endoscopic gastric or duodenal bleeding** by Week 12 and Week 24</measure>
    <time_frame>at 12, 24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">416</enrollment>
  <condition>Peptic Ulcer</condition>
  <arm_group>
    <arm_group_label>DWP14012 20mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>orally, once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lansoprazole 15mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>orally, once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DWP14012 20mg</intervention_name>
    <description>DWP14012 20mg, tablet, orally, once daily for up to 24 weeks</description>
    <arm_group_label>DWP14012 20mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lansoprazole 15 mg</intervention_name>
    <description>Lansoprazole 15mg capsule, orally, once daily for up to 24 weeks</description>
    <arm_group_label>Lansoprazole 15mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DWP14012 20mg placebo</intervention_name>
    <description>DWP14012 20mg placebo-matching tablet, orally, once daily for up to 24 weeks</description>
    <arm_group_label>Lansoprazole 15mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lansoprazole 15 mg placebo</intervention_name>
    <description>Lansoprazole 15mg placebo matching capsule, orally, once daily for up to 24 weeks</description>
    <arm_group_label>DWP14012 20mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male and female adults aged â‰¥ 19 years at the time of informed consent&#xD;
&#xD;
          2. Subjects who are diagnosed with musculoskeletal disease at screening and require&#xD;
             continued treatment with NSAIDs for at least 24 weeks&#xD;
&#xD;
          3. Subjects with at least one of the following risk factors for ulcer development at&#xD;
             screening.&#xD;
&#xD;
          4. Subjects who have no gastric or duodenal mucosal break or have ulcer in the scarring&#xD;
             stage based on the EGD result at screening.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects with esophagitis, gastroesophageal varix, esophagus, Barrett's esophagus,&#xD;
             acute gastrointestinal bleeding and else based on the screening EGD results.&#xD;
&#xD;
          2. Subjects who have undergone gastroduodenal surgery or total small bowel resection&#xD;
&#xD;
          3. Subjects with history of clinically significant disease of hepatic, renal, nervous,&#xD;
             pulmonary, endocrine, hemato-oncologic, cardiovascular or urinary system&#xD;
&#xD;
          4. Subjects who have had a malignant tumor in the last 5 years&#xD;
&#xD;
          5. Subjects who history of hypersensitivity to the IP ingredients, aspirin and NSAIDs&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>ChangKeun Lee, M.D, Ph.D.</last_name>
    <phone>02-3010-3284</phone>
    <email>cklee@amc.seoul.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 3, 2021</study_first_submitted>
  <study_first_submitted_qc>March 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 5, 2021</study_first_posted>
  <last_update_submitted>March 4, 2021</last_update_submitted>
  <last_update_submitted_qc>March 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peptic Ulcer</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lansoprazole</mesh_term>
    <mesh_term>Dexlansoprazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

